Pfizer Forecasts $ 54 Billion In 2022 Sales From Its Covid-19 Vaccine, Treatment

As Pfizer Inc. forecasts strong sales this year for its Covid-19 vaccine and treatment, the drugmaker is on the hunt for deals to bolster its pipeline of experimental products.

Pfizer said Tuesday that surging sales of its Covid-19 treatment and continued demand for its shots should boost the company’s revenue to around $ 100 billion this year. The company estimated that sales of its antiviral pill Paxlovid will reach about $ 22 billion while the vaccine will add $ 32 billion.